

Nikolaos Perakakis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3506055/publications.pdf>

Version: 2024-02-01

40
papers

2,258
citations

304743

22
h-index

330143

37
g-index

40
all docs

40
docs citations

40
times ranked

3701
citing authors

#	ARTICLE	IF	CITATIONS
1	Physiology and role of irisin in glucose homeostasis. <i>Nature Reviews Endocrinology</i> , 2017, 13, 324-337.	9.6	403
2	Obesity as a Disease. <i>Medical Clinics of North America</i> , 2018, 102, 13-33.	2.5	256
3	Pharmacotherapy of obesity: Available medications and drugs under investigation. <i>Metabolism: Clinical and Experimental</i> , 2019, 92, 170-192.	3.4	184
4	Irisin in metabolic diseases. <i>Endocrine</i> , 2018, 59, 260-274.	2.3	178
5	Pharmacotherapy of type 2 diabetes: An update. <i>Metabolism: Clinical and Experimental</i> , 2018, 78, 13-42.	3.4	144
6	Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease. <i>Endocrinology and Metabolism</i> , 2018, 33, 33.	3.0	120
7	Stem cells in the treatment of diabetes mellitus " Focus on mesenchymal stem cells. <i>Metabolism: Clinical and Experimental</i> , 2019, 90, 1-15.	3.4	88
8	Omics, big data and machine learning as tools to propel understanding of biological mechanisms and to discover novel diagnostics and therapeutics. <i>Metabolism: Clinical and Experimental</i> , 2018, 87, A1-A9.	3.4	83
9	Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study. <i>Metabolism: Clinical and Experimental</i> , 2019, 101, 154005.	3.4	83
10	Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement. <i>Metabolism: Clinical and Experimental</i> , 2019, 96, 66-82.	3.4	72
11	The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2020, 111, 154320.	3.4	68
12	Circulating levels of gastrointestinal hormones in response to the most common types of bariatric surgery and predictive value for weight loss over one year: Evidence from two independent trials. <i>Metabolism: Clinical and Experimental</i> , 2019, 101, 153997.	3.4	62
13	Leptin in Leanness and Obesity. <i>Journal of the American College of Cardiology</i> , 2021, 77, 745-760.	2.8	49
14	Leptin alters energy intake and fat mass but not energy expenditure in lean subjects. <i>Nature Communications</i> , 2020, 11, 5145.	12.8	48
15	Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six-month, randomized, placebo-controlled, double-blind clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1487-1492.	4.4	38
16	Follistatins in glucose regulation in healthy and obese individuals. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 683-690.	4.4	36
17	Regulation of the activins-follistatins-inhibins axis by energy status: Impact on reproductive function. <i>Metabolism: Clinical and Experimental</i> , 2018, 85, 240-249.	3.4	32
18	Physiology of Activins/Follistatins: Associations With Metabolic and Anthropometric Variables and Response to Exercise. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3890-3899.	3.6	31

#	ARTICLE	IF	CITATIONS
19	Quantifying Fibrinogen-Dependent Aggregation of Red Blood Cells in Type 2 Diabetes Mellitus. <i>Biophysical Journal</i> , 2020, 119, 900-912.	0.5	31
20	Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial. <i>Cardiovascular Diabetology</i> , 2019, 18, 141.	6.8	30
21	Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e390-e400.	3.6	29
22	Antitumor and antimetastatic effects of walnut oil in esophageal adenocarcinoma cells. <i>Clinical Nutrition</i> , 2018, 37, 2166-2171.	5.0	25
23	Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?. <i>Metabolism: Clinical and Experimental</i> , 2019, 98, iii-ix.	3.4	24
24	Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis. <i>Liver International</i> , 2021, 41, 1853-1866.	3.9	21
25	The Role of Glicentin and Oxyntomodulin in Human Metabolism: New Evidence and New Directions. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3003-e3005.	3.6	19
26	Adiponectin administration prevents weight gain and glycemic profile changes in diet-induced obese immune deficient Rag1 ^{fl/fl} /Rag2 ^{fl/fl} mice lacking mature lymphocytes. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1720-1730.	3.4	15
27	Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6332.	4.1	15
28	The Selective Peroxisome Proliferator-Activated Receptor Gamma Modulator CHS131 Improves Liver Histopathology and Metabolism in a Mouse Model of Obesity and Nonalcoholic Steatohepatitis. <i>Hepatology Communications</i> , 2020, 4, 1302-1315.	4.3	13
29	Fasting oxyntomodulin, glicentin, and gastric inhibitory polypeptide levels are associated with activation of reward and attention-related brain centres in response to visual food cues in adults with obesity: A cross-sectional functional MRI study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1202-1207.	4.4	9
30	Immune therapy in type 1 diabetes mellitus - Attempts to untie the Gordian knot?. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1278-1285.	3.4	8
31	Methods paper: Performance characteristics of novel assays for circulating levels of proglucagon-derived peptides and validation in a placebo controlled cross-over randomized clinical trial. <i>Metabolism: Clinical and Experimental</i> , 2022, 129, 155157.	3.4	8
32	Free IGF-1, Intact IGFBP-4, and PicoPAPP-A are Altered in Acute Myocardial Infarction Compared to Stable Coronary Artery Disease and Healthy Controls. <i>Hormone and Metabolic Research</i> , 2019, 51, 112-119.	1.5	7
33	Circulating profile of Activin-Follistatin-Inhibin Axis in women with hypothalamic amenorrhea in response to leptin treatment. <i>Metabolism: Clinical and Experimental</i> , 2020, 113, 154392.	3.4	7
34	Metabolic regulation of activins in healthy individuals and in obese patients undergoing bariatric surgery. <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 36, e3297.	4.0	7
35	Sex specific effect of ATPase inhibitory factor 1 on body weight: studies in high fat diet induced obese mice and genetic association studies in humans. <i>Metabolism: Clinical and Experimental</i> , 2020, 105, 154171.	3.4	6
36	Branched-Chain Amino Acids in relation to food preferences and insulin resistance in obese subjects consuming walnuts: A cross-over, randomized, double-blind, placebo-controlled inpatient physiology study. <i>Clinical Nutrition</i> , 2021, 40, 3032-3036.	5.0	5

#	ARTICLE	IF	CITATIONS
37	PCSK9 and ANGPTL3 levels correlate with hyperlipidemia in HIV-lipoatrophy, are regulated by fasting and are not affected by leptin administered in physiologic or pharmacologic doses. <i>Metabolism: Clinical and Experimental</i> , 2022, 134, 155265.	3.4	4
38	Research advances in metabolism 2016. <i>Metabolism: Clinical and Experimental</i> , 2017, 67, 41-53.	3.4	0
39	Research advances in metabolism 2017. <i>Metabolism: Clinical and Experimental</i> , 2018, 83, 280-289.	3.4	0
40	Both Elafibranor and Liraglutide Improve NAFLD / NASH but Affect Differentially the Hepatic Lipidome and Metabolome in a Diet-Induced Obese and Biopsy-Confirmed Mouse Model of NASH. <i>Journal of the Endocrine Society</i> , 2021, 5, A314-A315.	0.2	0